deepCDR Biologics
deepCDR Biologics is a Basel-based, privately held biotechnology company founded in 2019, operating with 1–10 employees to provide what it describes as cutting-edge, scalable biotechnology technologies and services, with no commercialized product or disclosed customer base in the available evidence.
- Company typePrivate
- Founded2019
- HeadquartersBasel, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingServices
What deepCDR Biologics does
deepCDR Biologics is a privately held biotechnology company founded in 2019 and headquartered in Basel, Switzerland. The company self-describes as a provider of 'cutting-edge technologies and services, offering scalable solutions,' but the input data does not specify the therapeutic area, modality, or technical platform. Its public profile is limited, with a headcount of 1–10 employees and a corporate website at deepcdr.com. The founding team comprises Sai Reddy (co-founder & chairman), Cedric Weber (Co-Founder & Director of Technology), Derek Mason, and Simon Friedensohn. No management team beyond the founders is disclosed, and no named products, services lines, scientific publications, patents, or partnerships are reflected in the available data. The same data set contains detailed records for Alloy Therapeutics (a separate U.S.-based transgenic antibody discovery platform), but those products, customers, and platforms cannot be attributed to deepCDR Biologics in this analysis.
Financially, deepCDR Biologics appears to be at a very early stage. Its only documented capital sources are two Venture Kick seed grants totaling approximately $82,382, awarded in January 2020 (the first roughly $41,096 led by Venture Kick and the second roughly $41,286 also from Venture Kick). There is no information on institutional venture funding, revenue, customers, pricing, or contracts. Given the minimal footprint, the company is most plausibly positioned as a pre-revenue research or technology-development entity, with go-to-market, revenue model, and customer segments effectively unspecified in the available evidence. The dominant data gap is the complete absence of post-2020 commercial, hiring, or funding activity.
deepCDR Biologics firmographics
Firmographics- Name
- deepCDR Biologics
- Legal name
- Alloy Therapeutics, Inc.
- Website
- https://deepcdr.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- deepCDR Biologics is a Basel-based, privately held biotechnology company founded in 2019, operating with 1–10 employees to provide what it describes as cutting-edge, scalable biotechnology technologies and services, with no commercialized product or disclosed customer base in the available evidence.
- Ownership category
- akta.pro rank
deepCDR Biologics industry classification
Industry- Product category
- Biotechnology Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where deepCDR Biologics is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
deepCDR Biologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Platform Licensing (ATX-GX™): Licensing of proprietary transgenic mouse platforms to pharmaceutical and biotech partners, enabling access to foundational biologics discovery technologies with flexible business terms.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
deepCDR Biologics product offering
Product offeringCore offering
deepCDR Biologics is a Basel-based biotechnology company founded in 2019 that provides cutting-edge biotechnology technologies and services with scalable solutions. The company focuses on serving the biologics development needs of pharmaceutical and biotechnology clients with offerings positioned as scalable, technology-driven services.
Product overview
Alloy Therapeutics is a biotechnology company offering a comprehensive platform of antibody discovery services and related biologics technologies. The core offerings include the ATX-GX™ transgenic mouse platform for fully human antibody discovery, monoclonal and bispecific antibody discovery services, and antibody optimization workflows. These are supported by proprietary AI/ML tools (Alloy Insights) for clone selection and in silico design. The portfolio extends to TCR Mimics, Genetic Medicines, and Cell Therapies, providing an integrated ecosystem for drug discovery from target identification through lead optimization.
Differentiator
Problem solved
Functional benefit
Brands
- ATX-GX™: Licensed transgenic platform for human antibody discovery with flexible business terms
Quantifiable outcome
- 200+ partners utilizing the platform globally
- +2 more outcomes
Companies that use deepCDR Biologics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
deepCDR Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
deepCDR Biologics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Institute for Protein InnovationcoreStrategic collaboration to advance next-generation antibody discovery. The partnership combines Institute for Protein Innovation's protein science expertise with Alloy Therapeutics' antibody discovery platforms to accelerate therapeutic development.
Scale indicators3 records
Recent moves3 records
Expansion highlights2 records
deepCDR Biologics competitors and assessment
Company assessmentBroad incumbents
- GenScript ProBio: GenScript ProBio offers antibody discovery, engineering and biomanufacturing services — a broad incumbent comparable on customer segment and end-to-end biologics service offering.
- Distributed Bio (Charles River Laboratories): Distributed Bio's antibody discovery platform (TAb platform, SuperHuman library) is now part of Charles River Laboratories — a broad incumbent offering antibody discovery services as part of a wider CRO portfolio, directly comparable on customer base and offering.
- WuXi Biologics: WuXi Biologics provides end-to-end biologics discovery, development and manufacturing services including antibody discovery platforms — a broad incumbent that any antibody-discovery services company competes against for biopharma R&D outsourcing budgets.
- Ablexis / AlivaMab Discovery (AstraZeneca): Ablexis's AlivaMab transgenic mouse antibody platform was acquired by AstraZeneca — a relevant comparable on the transgenic antibody discovery platform side, although now embedded inside a major pharma R&D organization.
Direct peers
- Alloy Therapeutics: Alloy Therapeutics operates a transgenic antibody discovery platform (ATX-GX™) with AI/ML-driven clone selection and bispecific engineering capabilities — the same product/customer category (biopharma antibody discovery services) deepCDR Biologics addresses, but at significantly greater scale (200+ partners, 20+ partner INDs).
- AbCellera Biologics: AbCellera is a publicly listed antibody discovery platform using AI/ML and high-throughput single-cell screening to discover therapeutic antibodies — directly comparable technology/market overlap with deepCDR's stated 'cutting-edge' antibody focus.
- Adimab: Adimab offers a proprietary antibody discovery and optimization platform via partnership-based licensing to pharma and biotech — a direct business-model and offering analogue in the antibody engineering services space.
Emerging players
- Biolojic Design: Biolojic Design applies AI/ML-driven computational design to antibody engineering — an early-stage, niche AI-native antibody player comparable to the deepCDR positioning around machine-learning-driven CDR engineering.
- Specifica (AstraZeneca): Specifica built an antibody discovery platform using in vitro display and proprietary libraries before being acquired by AstraZeneca — comparable to deepCDR as an early-stage antibody platform that ultimately required a large-pharma acquirer to commercialize.
Regional players
- Harbour BioMed: Harbour BioMed operates a transgenic mouse (Harbour Mice®) antibody discovery platform — directly comparable platform technology; though based in Asia/global rather than Switzerland, it targets the same biopharma antibody-discovery licensing customer segment.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks4 records
Key highlights3 records
Customer concentration
deepCDR Biologics social profiles
Digital presencedeepCDR Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
deepCDR Biologics leadership team
Management profileNumber of profiles
Profiles4 records
deepCDR Biologics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
deepCDR Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about deepCDR Biologics
What does deepCDR Biologics do?
deepCDR Biologics is a Basel-based biotechnology company founded in 2019 that provides cutting-edge biotechnology technologies and services with scalable solutions. The company focuses on serving the biologics development needs of pharmaceutical and biotechnology clients with offerings positioned as scalable, technology-driven services.
Is deepCDR Biologics a public or private company?
deepCDR Biologics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was deepCDR Biologics founded?
deepCDR Biologics was founded in 2019. It employs 1 to 10 people.
Where is deepCDR Biologics based?
deepCDR Biologics is headquartered in Basel, Switzerland, in the Europe region.
How does deepCDR Biologics make money?
One revenue line is on record: platform Licensing (ATX-GX™).
Who are deepCDR Biologics's main competitors?
Broad incumbents on record are GenScript ProBio, Distributed Bio (Charles River Laboratories), WuXi Biologics and Ablexis / AlivaMab Discovery (AstraZeneca). Direct peers are Alloy Therapeutics, AbCellera Biologics and Adimab. Emerging players are Biolojic Design and Specifica (AstraZeneca). Harbour BioMed is listed as a regional player.
Does deepCDR Biologics have an API?
No public API is recorded for deepCDR Biologics.
What industry is deepCDR Biologics in?
deepCDR Biologics's product category is Biotechnology Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.